Pfizer Betting Big on Cancer Research in $11.4 Billion Acquisition of Array BioPharma

Pfizer is delving deeper into cancer research with a roughly $11.4 billion deal for Array BioPharma, a drug developer that has seen its shares soar since announcing positive clinical trial results earlier this spring. Pfizer said Monday it will pay $48 per share in cash for Array, whose product portfolio includes a treatment combination used […]